Drug Trial Radar · NCT07295951
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Nov 18, 2025
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Conditions
- Acute Lymphoblastic Leukemia
- Acute Leukemias
- Acute Myeloid Leukemia
Interventions
14C-bleximenibDrug
14C-bleximenib will be administered orally.
bleximenibDrug
Non-radiolabeled bleximenib will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Dose Excreted in Urine (feu)Time frame: Up to Day 28
- Percentage of Dose Excreted in Feces (fef)Time frame: Up to Day 28
- Amount Excreted in Urine (Aeu)Time frame: Up to Day 28
- Amount Excreted in Feces (Aef)Time frame: Up to Day 28
- Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)
- Maximum Observed Concentration (Cmax)Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.